Job Description
Biopharm Research China (BRC) is one of the research units in Novo Nordisk China R & D and a fully integrated part of the Biopharmaceuticals Research Unit (BRU) in Denmark. We are committed to developing innovative biologics to improve the lives of people with haemophilia, growth disorders and autoimmune inflammatory diseases. By leveraging our core competences in protein and antibody engineering & production, we support Novo Nordisk pipeline projects in turning naturally occurring proteins into valuable pharmaceuticals and contribute to the identification of new molecular targets for the treatment of diseases. Currently BRC has three research departments. Molecular Biology Department We develop and master state-of-the-art bacterial and mammalian expression systems for the production of recombinant proteins in support of our portfolio. We are also engaged in the development of advanced technology platforms for antibody engineering including antibody humanization, phage display, E. coli display and associated high throughput screening capacity. We are constantly striving on building competences in the field of molecular antibody technology to modify, engineer and express proteins with desirable profiles. Protein Chemistry Department We are passionate and rigorous about proteins. We develop and implement advanced protein purification and characterization technologies for production of high quality bacterial / mammalian expressed recombinant proteins and in-house generated antibodies. Guided by protein structure determination and modern bioinformatics tools, we design proteins with improved biophysical and biological profiles. Together with our globalized R & D teams, we are actively involved in formulation and promotion of new ideas and innovations. Cell Biology Department We are responsible for the establishment of immunotechnology platforms and expertise in in vitro mammalian cell biology in support of our portfolio. We focus on assay antibody generation and production using hybridoma technology as well as cell based functional assays. We are dedicated in building competences in disease biology and understanding within our therapy areas. In addition, we are very engaged in presenting new potential drug targets to secure expansion and quality in our international project portfolio. Our ability to excel depends on the integrity, knowledge, dedication, and teamwork from each employee. Working with us, you will have the opportunity to collaborate with talented colleagues in an international environment, while developing and expanding your career. Welcome to BRC! Responsibility: This position requires a highly motivated interactive and creative scientist to carry out scientific computing tasks including protein structure modeling, prediction, molecule design as well as database establishment, maintenance and management. Requirements: • Ph.D . in physics, bioinformatics, structural biology or related discipline with> 2yrs of post-doc training. • Hand-on experience with protein structure modeling software as MODELLER, DOCK • Knowledge in a broad range of contemporary statistical methods for classification and prediction. • Familiarity with Discovery Studio software suite is preferred • Demonstrated computation skills, eg programming and data mining. • Ability and desire to work both independently and collaboratively in a dynamic, innovative, and interdependent research environment. • Industrial experience is a plus. • Excellent oral and written communication skills.
Contact: Miss Zheng
Address: 300 Huaihai Zhong Road, Shanghai Hong Kong New World Tower, 35th floor 3501-3502
Novo Nordisk is the world's leading biopharmaceutical company, insulin for diabetes treatment in the development and production of world leader. Novo Nordisk is headquartered in Copenhagen, Denmark, employs approximately 21,000 people in more than 70 countries and markets its products in 179 countries. In Europe are built production plant.
In early 1994, Novo Nordisk Board adopted a strategic investment in China plans to establish in Beijing Novo Nordisk (China) Pharmaceutical Co., Ltd. Headquarters and biotechnology research and development center, the construction of modern production plant in Tianjin, and in the country's 30 cities established a perfect marketing system. For more information, please visit Novo Nordisk China website.
Novo Nordisk is the world's leading biopharmaceutical company, insulin for diabetes treatment in the development and production of world leader. Novo Nordisk is headquartered in Copenhagen, Denmark, employs approximately 21,000 people in more than 70 countries and markets its products in 179 countries. In Europe are built production plant.
In early 1994, Novo Nordisk Board adopted a strategic investment in China plans to establish in Beijing Novo Nordisk (China) Pharmaceutical Co., Ltd. Headquarters and biotechnology research and development center, the construction of modern production plant in Tianjin, and in the country's 30 cities established a perfect marketing system. For more information, please visit Novo Nordisk China website.
0 comments:
POST A COMMENT